MCID: CNT093
MIFTS: 30

Central Nervous System Teratoma

Categories: Neuronal diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Central Nervous System Teratoma

MalaCards integrated aliases for Central Nervous System Teratoma:

Name: Central Nervous System Teratoma 12 15 73
Teratoma of the Central Nervous System 59
Cns Teratoma 12

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3640
NCIt 50 C5441
Orphanet 59 ORPHA252018
UMLS 73 C1332895

Summaries for Central Nervous System Teratoma

MalaCards based summary : Central Nervous System Teratoma, also known as teratoma of the central nervous system, is related to teratoma and adult central nervous system teratoma. An important gene associated with Central Nervous System Teratoma is NES (Nestin), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Cytoskeleton remodeling Neurofilaments. The drugs Cisplatin and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells.

Related Diseases for Central Nervous System Teratoma

Graphical network of the top 20 diseases related to Central Nervous System Teratoma:



Diseases related to Central Nervous System Teratoma

Symptoms & Phenotypes for Central Nervous System Teratoma

Drugs & Therapeutics for Central Nervous System Teratoma

Drugs for Central Nervous System Teratoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
3
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
4
Ondansetron Approved Phase 3 99614-02-5 4595
5 Antiemetics Phase 3,Phase 1
6 Autonomic Agents Phase 3,Phase 1
7 BB 1101 Phase 3,Phase 1
8 Dexamethasone acetate Phase 3,Phase 1 1177-87-3
9 Emetics Phase 3
10 Gastrointestinal Agents Phase 3,Phase 1
11 Peripheral Nervous System Agents Phase 3,Phase 1
12
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
13
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
14
Ifosfamide Approved Phase 2,Phase 1 3778-73-2 3690
15
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
16
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
17
Thiotepa Approved, Investigational Phase 2,Phase 1 52-24-4 5453
18
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
19
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
20
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
21 Alkylating Agents Phase 2,Phase 1
22 Antineoplastic Agents, Alkylating Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
24 Etoposide phosphate Phase 2,Phase 1
25 Immunosuppressive Agents Phase 2,Phase 1
26
Isophosphamide mustard Phase 2,Phase 1 0
27 Topoisomerase Inhibitors Phase 2,Phase 1
28 Liver Extracts Phase 1, Phase 2
29 Protein Kinase Inhibitors Phase 1, Phase 2
30
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
31
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
32
Fluorouracil Approved Phase 1 51-21-8 3385
33
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
34
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 5310940 9887054 43805 6857599
35
Sunitinib Approved, Investigational Phase 1 341031-54-7, 557795-19-4 5329102
36
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
37
Vincristine Approved, Investigational Phase 1 2068-78-2, 57-22-7 5978
38
Acetylcysteine Approved, Investigational Phase 1 616-91-1 12035
39
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 1 58-05-9 143 6006
42
Vitamin A Approved, Nutraceutical, Vet_approved Phase 1 11103-57-4, 68-26-8 445354
43 Histone Deacetylase Inhibitors Phase 1
44 Antidotes Phase 1
45 Antimetabolites Phase 1
46 Antimetabolites, Antineoplastic Phase 1
47 Bone Density Conservation Agents Phase 1
48 Calcium, Dietary Phase 1
49 Micronutrients Phase 1
50 Protective Agents Phase 1

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
2 Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Completed NCT00047320 Phase 2 carboplatin;etoposide;ifosfamide;thiotepa
3 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
4 Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors Completed NCT00002472 Phase 2 cisplatin;etoposide
5 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
6 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
7 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
8 Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Completed NCT00929903 Phase 1 pazopanib hydrochloride
9 Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Completed NCT00281944 Phase 1 oxaliplatin;fluorouracil;leucovorin calcium
10 Sunitinib in Treating Young Patients With Refractory Solid Tumors Completed NCT00387920 Phase 1 sunitinib malate
11 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
12 PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
13 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
14 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
15 Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
16 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
17 Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors Withdrawn NCT00897858

Search NIH Clinical Center for Central Nervous System Teratoma

Genetic Tests for Central Nervous System Teratoma

Anatomical Context for Central Nervous System Teratoma

MalaCards organs/tissues related to Central Nervous System Teratoma:

41
Brain, Spinal Cord, T Cells, Liver, Bone

Publications for Central Nervous System Teratoma

Articles related to Central Nervous System Teratoma:

# Title Authors Year
1
Primary central nervous system teratoma with sarcomatous transformation in a young girl: Report of a rare case. ( 27695574 )
2016
2
Management of central nervous system teratoma. ( 25150764 )
2014

Variations for Central Nervous System Teratoma

Expression for Central Nervous System Teratoma

Search GEO for disease gene expression data for Central Nervous System Teratoma.

Pathways for Central Nervous System Teratoma

Pathways related to Central Nervous System Teratoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.28 NES SOX2
2
Show member pathways
10.99 GFAP NES
3 10.7 GFAP NES SOX2

GO Terms for Central Nervous System Teratoma

Cellular components related to Central Nervous System Teratoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.96 GFAP NES
2 intermediate filament cytoskeleton GO:0045111 8.62 GFAP NES

Biological processes related to Central Nervous System Teratoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to wounding GO:0009611 8.62 GFAP SOX2

Molecular functions related to Central Nervous System Teratoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 8.62 GFAP NES

Sources for Central Nervous System Teratoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....